Plain-English translation of NCT05249634 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research study is testing a medication called JATENZO to see if it can safely increase testosterone levels in men who have both low testosterone and chronic kidney disease. The study will also measure whether the treatment improves related symptoms like muscle strength, energy, sexual function, and the number of red blood cells in your blood. Researchers will monitor you closely over six months to see how your body responds.
Men with chronic kidney disease often develop low testosterone, which can cause fatigue, weakness, mood changes, and other symptoms—but there isn't much research on whether this medication is safe and effective for this specific group of patients. This study aims to fill that gap.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth every day for six months. During that time, you'll visit the research clinic every two to four weeks for blood tests, brief physical exams, blood pressure checks, and questionnaires about your symptoms and wellbeing. The research team will also measure your body composition using a scan and test your muscle strength. Your dose may be adjusted based on your testosterone levels, and the researchers will watch carefully for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
St. Louis University
Collaborators
Clarus Therapeutics, Inc.
Enrollment target
~20 participants
Started
March 2022
Primary completion
June 2028
Age range
18 Years – 85 Years
Sex
Male only
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sandeep Dhindsa, MD
St. Louis University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.